US Biotechnology "10 Key Takeaways from Our PTH Doc Dinner in Chicago at..."

研报英文原文证据摘录

US Biotechnology "10 Key Takeaways from Our PTH Doc Dinner in Chicago at..."

Global Research

13 June 2026ab

US Biotechnology Equities

Americas10 Key Takeaways from Our PTH Doc Dinner in

Chicago at ENDO Biotechnology

Michael Yee

Analyst

michael.yee@ubs.com

We hosted Dr. Daniel Katselnik, an endocrinologist/trial investigator from Texas, for an +1-305-536 9101

investor dinner in Chicago during ENDO 2026. He treats ~40–50 hypoPT patients, ~10–

Dina Elmonshed

20% of whom are currently on the PTH replacement therapy – which is above average

and broadly in line with other physicians we have screened. See our 10 key takeaways dina.elmonshed@ubs.com

below: +1-212-649 8276

Kyle Yang, CFA

1. The pill burden is real: Some patients need to take 10–20 pills per day, including 2 Associate Analyst

or more vitamin D pills and 3–4g or more calcium (which equates to ~6–8 tablets). kyle.yang@ubs.com

Nearly everyone on PTH replacement therapy is satisfied with injections, particularly +1-212-713 1458

patients who previously had a heavy pill burden. Matthew Hagood

Associate Analyst

2. Doc sees a maximum of 30-40% of his patients getting on PTH replacement matthew.hagood@ubs.com

+1-212-713 1107

therapies: At most, he would likely put ~30–40% of his patients on a PTH replacement

therapy – primarily those with more severe disease and high pill burden. If patients are Madeleine Lee

doing well on only a few pills/tablets per day (which are very cheap with de minimis Associate Analyst

costs), there is little reason to switch to PTH replacement therapy. madeleine.lee@ubs.com

+1-212-713 1476

Roy Zawadzki, PhD3. Insurance remains a hurdle: Every patient he prescribed Yorvipath required prior

authorization, including documentation that conventional therapies were insufficient to

roy.zawadzki@ubs.com